Editorial: Pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus (T2DM).
作者信息
Luo Jian-Quan, Shu Yan, Zhang Wei
机构信息
Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.
Institute of Clinical Pharmacy, Central South University, Changsha, China.
出版信息
Front Endocrinol (Lausanne). 2023 Sep 18;14:1287807. doi: 10.3389/fendo.2023.1287807. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus (T2DM).社论：2型糖尿病（T2DM）中的药物基因组学和药物微生物组学
Front Endocrinol (Lausanne). 2023 Sep 18;14:1287807. doi: 10.3389/fendo.2023.1287807. eCollection 2023.
2
Pharmacomicrobiomics: a novel route towards personalized medicine?药物微生物组学：迈向个体化医学的新途径？
Protein Cell. 2018 May;9(5):432-445. doi: 10.1007/s13238-018-0547-2. Epub 2018 Apr 28.
3
Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine.药物反应与药物基因组学和药物微生物组学的关联：迈向更好的个性化医疗。
Brief Bioinform. 2021 Jul 20;22(4). doi: 10.1093/bib/bbaa292.
4
Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.2 型糖尿病的药物遗传学：迈向个体化医学的途径。
Diabetes Metab Res Rev. 2019 Mar;35(3):e3109. doi: 10.1002/dmrr.3109. Epub 2019 Jan 7.
5
Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment.药物微生物组学与 2 型糖尿病：一种新的治疗视角。
Front Endocrinol (Lausanne). 2023 Mar 23;14:1149256. doi: 10.3389/fendo.2023.1149256. eCollection 2023.
6
Current progress in pharmacogenomics of Type 2 diabetes: A systemic overview.2 型糖尿病的药物基因组学研究进展：系统综述。
Diabetes Metab Syndr. 2021 Sep-Oct;15(5):102239. doi: 10.1016/j.dsx.2021.102239. Epub 2021 Aug 3.
7
Precision medicine: The future in diabetes care?精准医学：糖尿病护理的未来？
Diabetes Res Clin Pract. 2016 Jul;117:12-21. doi: 10.1016/j.diabres.2016.04.033. Epub 2016 Apr 26.
8
Pharmacomicrobiomics-Guided Precision Oncology: A New Frontier of P4 (Predictive, Personalized, Preventive, and Participatory) Medicine and Microbiome-Based Therapeutics.精准肿瘤药理学引导的精准肿瘤药理学：精准医学和基于微生物组的治疗学的新前沿，包括预测性、个性化、预防性和参与性医学和基于微生物组的治疗学。
OMICS. 2024 Jan;28(1):5-7. doi: 10.1089/omi.2023.0254. Epub 2024 Jan 8.
9
Pharmacogenetics and personalized treatment of type 2 diabetes.药物遗传学与 2 型糖尿病的个体化治疗。
Biochem Med (Zagreb). 2013;23(2):154-71. doi: 10.11613/bm.2013.020.
10
The Importance of Precision Medicine in Type 2 Diabetes Mellitus (T2DM): From Pharmacogenetic and Pharmacoepigenetic Aspects.精准医学在2型糖尿病（T2DM）中的重要性：从药物遗传学和药物表观遗传学角度
Endocr Metab Immune Disord Drug Targets. 2019;19(6):719-731. doi: 10.2174/1871530319666190228102212.
本文引用的文献
1
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression.糖尿病肾病：治疗进展减缓支柱的最新进展。
Diabetes Care. 2023 Sep 1;46(9):1574-1586. doi: 10.2337/dci23-0030.
2
Hydrochlorothiazide-induced glucose metabolism disorder is mediated by the gut microbiota via LPS-TLR4-related macrophage polarization.氢氯噻嗪诱导的葡萄糖代谢紊乱由肠道微生物群通过脂多糖- Toll样受体4相关的巨噬细胞极化介导。
iScience. 2023 Jun 15;26(7):107130. doi: 10.1016/j.isci.2023.107130. eCollection 2023 Jul 21.
3
Global Prevalence of Prediabetes.全球糖尿病前期患病率。
Diabetes Care. 2023 Jul 1;46(7):1388-1394. doi: 10.2337/dc22-2376.
4
Pharmacogenomics: current status and future perspectives.药物基因组学：现状与未来展望。
Nat Rev Genet. 2023 Jun;24(6):350-362. doi: 10.1038/s41576-022-00572-8. Epub 2023 Jan 27.
5
Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment.药物微生物组学：在抗高血压治疗中利用药物与微生物群的相互作用
Front Med (Lausanne). 2022 Jan 19;8:742394. doi: 10.3389/fmed.2021.742394. eCollection 2021.
6
European versus Asian differences for the associations between paraoxonase-1 genetic polymorphisms and susceptibility to type 2 diabetes mellitus.欧洲人与亚洲人之间，对 1 型糖尿病易感性的芳香基酯酶 1 基因多态性关联存在差异。
J Cell Mol Med. 2018 Mar;22(3):1720-1732. doi: 10.1111/jcmm.13453. Epub 2018 Jan 4.
Zotero 插件